MBA MD - Cellectis Chief Officer

Cellectis Management Efficiency

The company has return on total asset (ROA) of (0.0743) % which means that it has lost $0.0743 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4802) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2025. Return On Capital Employed is likely to drop to -0.29 in 2025. At this time, Cellectis' Non Currrent Assets Other are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 243.1 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 58.8 M in 2025.

Similar Executives

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people. Cellectis SA (CLLS) is traded on NASDAQ Exchange in USA. It is located in 8, rue de la Croix Jarry, Paris, France, 75013 and employs 216 people. Cellectis is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Cellectis SA Leadership Team

Cellectis Stock Performance Indicators

Additional Tools for Cellectis Stock Analysis